Skip to main content

Table 2 Baseline characteristics of patients with measurements of mitral inflow available

From: The prognostic importance of a history of hypertension in patients with symptomatic heart failure is substantially worsened by a short mitral inflow deceleration time

 

Hypertension (n = 257)

No hypertension (n = 621)

 

Restrictive (n = 122)

Non-restrictive (n = 135)

Restrictive (n = 303)

Non-restrictive (n = 318)

Age (years)

74 (52;87)

75 (55;90)

74 (52;90)

76 (53;90)

Male gender

60%

55%

61%

61%

BMI (kg/m2) *

27.2 (18.0;35.3)

26.5 (19.5;36.0)

25.3 (18.4;35.3)

25.0 (18.4;36.7)

Decelleration time (ms) *

117 (87;138)

187 (145;278)

116 (84;137)

171 (143;296)

E/A ratio *

1.8 (0.6;3.4)

1.0 (0.6;2.6)

1.5 (0.6;3.1)

1.0 (0.6;3.1)

Creatinine clearance (mL/min/1.73 m2)

58 (18;97)

57 (21;99)

63 (29;100)

57 (26;96)

Wall motion index *

1.3 (0.5;2.0)

1.6 (0.6;2.0)

1.1 (0.5;2.0)

1.4 (0.6;2.0)

LVEF ≤45% *

64%

48%

75%

58%

Left ventricle posterior wall thickness (mm) *

12 (9;17)

11 (8;15)

11 (7;15)

10 (7;14)

Smokers

33%

28%

33%

24%

Diabetes mellitus *

19%

22%

13%

12%

Hyperlipidaemia

37%

30%

30%

30%

History of ischemic heart disease

44%

45%

44%

44%

Previous stroke or TIA

15%

17%

11%

10%

Atrial fibrillation

44%

35%

38%

38%

COPD

19%

29%

20%

24%

Medications at discharge:

    

Betablockers *

51%

59%

43%

47%

ACE inhibitors

55%

59%

65%

56%

Angiotensin II blockers *

12%

10%

5%

6%

Calcium channel blockers *

15%

25%

11%

12%

Diuretics

92%

96%

93%

92%

Statins

20%

21%

17%

20%

Nitrates *

11%

25%

16%

20%

Glycosides (digoxin)*

42%

27%

42%

37%

Oral anticoagulants

28%

24%

36%

31%

  1. Footnote: Continuous variables are presented as median 5th; 95th percentiles.* indicates p for difference between the four sub-groups <0.05.